Phase 2 N=64 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
Nausea and Vomiting
Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=98 Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
Hematologic Diseases · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Participant Responses — 20; 21; 9; 12 participants
Phase 2 N=49 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates) — 23; 9; 12; 9 Participants — p=0.03
N/A N=14 Effect of Ondansetron for Withdrawal Symptoms
Substance Withdrawal Syndrome
Primary: Change in Withdrawal Symptoms With Placebo and With Ondansetron — -22.08; -42.71 Percent change
Phase 1 N=24 Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 30.196; 30.892 ng/mL
N/A N=162 Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin
Cancer
Primary: Number of Patients Who Had Complete Response — 50; 42 participants — p=0.41
Phase 1 N=24 Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 32.096; 31.753 ng/mL
N/A N=40 Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Malignant Neoplasm
Primary: Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication — 65; 40 percentage of patients
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
Phase 2 N=52 The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries
Cardiac Output
Primary: Change in Cardiac Output From Baseline to 20 Minutes Post-spinal — -2.05; -1.92 L/min
Phase 4 N=98 Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy
Nausea and Vomiting, Postoperative
Primary: Incidence of Nausea — 46; 54 percentage of participants
Phase 1 N=18 Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water
Healthy Participants
Primary: Cmax — 40.866; 42.843; 39.382 ng/mL
Phase 4 N=70 Ondansetron for Bipolar Disorder and Alcohol Use Disorders
Bipolar Disorder · Alcohol Use Disorder · Dual Diagnosis
Primary: Hamilton Rating Scale for Depression (HAMD) — 13.77; 14.23; 8.52; 8.86 score on a scale
N/A N=28 Ondansetron and the QT Interval In Adult Emergency Department Patients
Ondansetron
Primary: Change in QTc Interval With Ondansetron Administration — 19.7 mS
Phase 4 N=141 Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
Post-operative Nausea and Vomiting
Primary: Nausea Scale — 3.5; 4.0; 4.0; 2.0 score on a scale
Phase 2 N=30 Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting
Nausea · Vomiting
Primary: Efficacy for the Prevention/Rescue of Radiation-induced Nausea and Vomiting. — 21; 4; 2; 0 Participants
N/A N=19 CSF Pharmacokinetics of Ondansetron
Pain
Primary: CSF to Plasma Concentration Ratio — 0.15 Ratio
Phase 3 N=75 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
Cancer of the Cervix
Primary: Percentage of Participants With Response Rate to Anti-Emetic Therapy Days 4-7 Each Chemotherapy Cycle — 49.8; 39.7 percentage of participants
Phase 2 N=136 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Nausea · Vomiting · Glioma
Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients
Phase 2 N=205 Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
Alcohol Abuse · Alcohol Dependence
Primary: Number of Alcoholic Containing Drinks Per Drinking Day — 5.9; 6.1; 5.9 Standard alcohol drinks per drinking day
Phase 4 N=62 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
Obsessive-Compulsive Disorder · Tic Disorders · Tourette Syndrome
Primary: Change in Brain Activation - Insula Cortex — -0.071; -0.0094 Parameter estimate of BOLD Signal Change
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale
Phase 2 N=48 Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
Nausea and Vomiting, Postoperative · Nausea With Vomiting Chemotherapy-Induced
Primary: Cmax — 37.282; 41.108 ng/mL
Phase 4 N=181 Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea
Nausea · Vomiting
Primary: Complete Response Rates Among Standard of Care and Combination Therapy Groups. — 58; 73; 31; 17 Participants — p=<.001
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 2 N=85 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Chemotherapy-induced Nausea and Vomiting
Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants
Phase 1 N=12 A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
Chemotherapy-Induced Nausea and Vomiting
Primary: Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC) of Ondansetron — 644; 712; 649 nM*hr
Phase 2 N=150 Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
Acute Myelogenous Leukemia · Chemotherapy-induced Nausea and Vomiting
Primary: Number of Patients With Complete Response — 11; 15; 18 participants
Phase 2 N=95 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 3.70; 3.60; 3.37; 3.99 drinks per drinking day — p=0.94
Phase 1 N=48 Two Way Bioequivalence Study Under Fed Conditions
Healthy
Primary: Area Under Plasma Concentration — 213.7; 225.9 ng*hr/ml — p=0.05